Controlling genital chlamydial infectionBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7066.1160 (Published 09 November 1996) Cite this as: BMJ 1996;313:1160
- Anne M Johnson,
- Lucia Grun,
- Andrew Haines
- Professor of epidemiology MRC health services research fellow Department of Sexually Transmitted Diseases, University College London Medical School, London WC1E 6AU
- Professor of primary health care Department of Primary Care and Population Sciences, Royal Free Hospital School of Medicine and University College London Medical School, London NW3 2PF
Advances in diagnosis and treatment may make screening worthwhile
Screening for asymptomatic Chlamydia trachomatis was first proposed in the early 1980s1 and guidelines for selective screening in the United States were published by the Centers for Disease Control in 1993.2 The condition fulfils many of the criteria for screening.3 Most infections are initially asymptomatic but may subsequently cause considerable long term morbidity.4 5 Treatment is simple and effective. So, is genital chlamydial infection worthy of a national selective screening programme in Britain?
C trachomatis is the most common curable sexually transmitted pathogen in Britain. Despite previous calls for more attention to be paid to the problem,6 no national screening guidelines are in place, although the Department of Health has recently formed an expert advisory group to address questions of control. The epidemiology of genital chlamydial infection has been incompletely studied. Screening, diagnosis, and treatment remain inconsistent. National surveillance of chlamydial infection is limited to returns from genitourinary medicine clinics and voluntary laboratory reporting.
Over 39 000 cases of genital chlamydial infection were treated in genitourinary medicine clinics in England and Wales in 1995, more than three times the number of cases of gonorrhoea reported.7 …